Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Abbvie Inc patents


Recent patent applications related to Abbvie Inc. Abbvie Inc is listed as an Agent/Assignee. Note: Abbvie Inc may have other listings under different names/spellings. We're not affiliated with Abbvie Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Abbvie Inc-related inventors


Automatic injection device

Systems, methods, and devices are disclosed for facilitating injection of a medicament using an automatic injection device. The automatic injection device includes a housing defining a confined inner space and having a length extending from a proximal end to a distal end along a longitudinal axis. A helical biasing member,... Abbvie Inc

Novel inhibitor compounds of phosphodiesterase type 10a

where Z1 to Z5, Ar1 to Ar5, Ra, R21, R22 and R23 are as defined in the claims.... Abbvie Inc

Substituted phthalazines

wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds... Abbvie Inc

2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.... Abbvie Inc

Amyloid-beta binding proteins

The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.... Abbvie Inc

Dose adjustment

This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.... Abbvie Inc

Indazolones as modulators of tnf signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.... Abbvie Inc

Carbidopa and l-dopa prodrugs and methods of use

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.... Abbvie Inc

Methods and compositions for treating asthma using anti-il-13 antibodies

The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.... Abbvie Inc

Spirocyclic hat inhibitors and methods for their use

or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by... Abbvie Inc

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.... Abbvie Inc

Monoclonal antibodies against amyloid beta protein and uses thereof

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.... Abbvie Inc

Synthetic route to anti-viral agents

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.... Abbvie Inc

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyppyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.... Abbvie Inc

Methods for treating hcv

The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a... Abbvie Inc

Enzyme compositions with reduced viral and microbial contamination

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.... Abbvie Inc

Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency

The present disclosure relates to pharmaceutical compositions comprising enzymes or enzyme mixtures having lipolytic and other optional other activities and methods of use thereof to treat exocrine pancreatic insufficiency.... Abbvie Inc

Novel inhibitor compounds of phosphodiesterase type 10a

wherein Y1 and Y2 are adjacent atoms in Het1, which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O,... Abbvie Inc

Levodopa and carbidopa intestinal gel and methods of use

The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.... Abbvie Inc

Anti-viral compounds

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Abbvie Inc

Indole and indoline derivatives and methods of use thereof

wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.... Abbvie Inc

Solid antiviral dosage forms

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.... Abbvie Inc

Treatment of filarial diseases

The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions... Abbvie Inc

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least... Abbvie Inc

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.... Abbvie Inc

Methods for modulating the glycosylation profile of recombinant proteins using sugars

The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells.... Abbvie Inc

Cell culture methods to reduce acidic species

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations.... Abbvie Inc

Anti-b7-h3 antibodies and antibody drug conjugates

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.... Abbvie Inc

Substituted indoles

... Abbvie Inc

Methods for treating spinal cord injury and pain

Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.... Abbvie Inc

Low acidic species compositions and methods for producing and using the same using displacement chromatography

The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα is detrimental, are also... Abbvie Inc

Methods to modulate lysine variant distribution

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.... Abbvie Inc

Interleukin -13 binding proteins

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding... Abbvie Inc

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-c]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.... Abbvie Inc

Protein purification using displacement chromatography

Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies... Abbvie Inc

11/23/17 / #20170333428

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the... Abbvie Inc

11/09/17 / #20170320880

Indane inhibitors of eed and methods of their use

or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.... Abbvie Inc

11/02/17 / #20170313786

Dual variable domain immunoglobulin and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.... Abbvie Inc

10/26/17 / #20170306009

Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen

The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells by supplementing the production media with dissolved oxygen.... Abbvie Inc

10/26/17 / #20170306010

Glycoengineered binding protein compositions

Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.... Abbvie Inc

09/28/17 / #20170274055

Enzyme compositions with reduced viral and microbial contamination

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.... Abbvie Inc

09/21/17 / #20170266289

Topical formulation

The invention described herein provides topical formulations that can be prepared at ambient temperature without the need for any heating step during preparation. Thus the formulations are particularly suitable for cosmetic and pharmaceutical active ingredients that are relatively heat sensitive. The invention also provides methods for preparing the same.... Abbvie Inc

09/07/17 / #20170253562

Nampt inhibitors

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.... Abbvie Inc

08/31/17 / #20170247445

Mammalian cell culture performance through surfactant supplementation of feed media

The present invention provides methods for increasing cell culture performance through the use of chemically defined feed media (CDFM). In particular, the present invention provides methods for the use of surfactants as supplements to CDFM to allow for higher concentrations of media components and thereby result in increased cell culture... Abbvie Inc

08/17/17 / #20170232000
08/10/17 / #20170226552

Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt

The present invention relates to the field of protein production and, in particular, to methods and compositions for modulating the glycosylation of recombinant proteins expressed in host cells using cell culture media supplemented with cobalt.... Abbvie Inc

08/10/17 / #20170226200

Dual variable domain immunoglobulins and uses thereof

Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.... Abbvie Inc

08/03/17 / #20170217850

Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose

The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.... Abbvie Inc

08/03/17 / #20170218091

Monovalent binding proteins

Disclosed herein are engineered monovalent binding proteins that bind to one or more antigens, as well as methods of making and using the binding proteins in the prevention, diagnosis, and/or treatment of disease.... Abbvie Inc

07/27/17 / #20170209344

Systems and methods for tubing delivery

Adapters for a connector assembly for percutaneous tubing are provided. A male adapter (FIG. 22a, 1000) includes a connector fitting (1002) proximate a first end, the connector fitting configured to join to a connector for a tubing system or device, and a male connector (656) proximate a second end. The... Abbvie Inc

07/27/17 / #20170210796

Stable dual variable domain immunoglobulin protein formulations

The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein. The invention also provides stable lyophilized formulations comprising a Lyophilized Stable Dual Variable Domain Immunoglobulin (LS-DVD-Ig) protein.... Abbvie Inc

07/13/17 / #20170197980

N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate

Docusate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.... Abbvie Inc

07/13/17 / #20170198034

Methods to control protein heterogeneity

The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.... Abbvie Inc

07/06/17 / #20170189402

Solid dosage forms

The present invention features solid dosage forms comprising two or more different active ingredients. In one embodiment, the present invention features a tablet dosage form comprising a first layer and a second layer, wherein the first layer comprises (1) 200 mg lopinavir, (2) ritonavir, (3) a pharmaceutically acceptable hydrophilic polymer,... Abbvie Inc

07/06/17 / #20170189426

Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form... Abbvie Inc

07/06/17 / #20170189620

Syringe with two-stage sealing pressure

A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. The sealing... Abbvie Inc

07/06/17 / #20170190692

Atrasentan mandelate salts

The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition... Abbvie Inc

06/29/17 / #20170181973

Formulations of pyrimidinedione derivative compounds

The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in... Abbvie Inc

06/29/17 / #20170182179

Antibody drug conjugates with cell permeable bcl-xl inhibitors

Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.... Abbvie Inc

06/29/17 / #20170182242

Wearable automatic injection device and related methods of use

Exemplary embodiments provide wearable automatic injection devices for providing an injection of a therapeutic agent into a patient. The wearable automatic injection device includes a housing having a patient contact portion securable to the patient, an injection needle for insertion into the patient, and a prefilled syringe assembly for holding... Abbvie Inc

06/22/17 / #20170172985

Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.... Abbvie Inc

06/22/17 / #20170172993

Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.... Abbvie Inc

06/22/17 / #20170173009

Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.... Abbvie Inc

Patent Packs
06/22/17 / #20170173270

Self-injection tool with movable needle shroud

Self-injection tool includes a base and a shroud member. The base includes a proximal end, a distal end, and a barrel engagement portion. The barrel engagement portion defines a cavity to receive at least a portion a syringe barrel such that the distal end of a needle extends a first... Abbvie Inc

06/22/17 / #20170174624

Primary carboxamides as btk inhibitors

pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.... Abbvie Inc

06/22/17 / #20170174688

Substituted indoles

wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds... Abbvie Inc

06/15/17 / #20170166633

Antibodies against the rgm a protein and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and... Abbvie Inc

06/08/17 / #20170156987

Systems and methods for tubing delivery

Connector assembly (FIG. 4a) includes a shell (210), a connector body (230), and a plug (250). The shell (210) has a sidewall (212) defining an interior, a first shell end having a first opening (214) defined therein, and a second shell end having a second opening (216) defined therein, each... Abbvie Inc

06/08/17 / #20170157104

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Abbvie Inc

06/08/17 / #20170157105

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Abbvie Inc

06/08/17 / #20170157206

High purity oritavancin and producing same

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.... Abbvie Inc

06/08/17 / #20170158666

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Abbvie Inc

06/08/17 / #20170158693

Hexahydrodiazepinoquinolines carrying a cyclic radical

The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of... Abbvie Inc

06/08/17 / #20170158760

Isolation and purification of antibodies using protein a affinity chromatography

Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography.... Abbvie Inc

06/08/17 / #20170158758

Low acidic species compositions and methods for producing and using the same

The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα... Abbvie Inc

06/01/17 / #20170151238

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the... Abbvie Inc

06/01/17 / #20170151343

Anti-hulrrc15 antibody drug conjugates and methods for their use

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.... Abbvie Inc

06/01/17 / #20170151344

Anti-hulrrc15 antibody drug conjugates and methods for their use

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.... Abbvie Inc

Patent Packs
05/25/17 / #20170145465

Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins

Protein glycosylation greatly influences the structure, function, and pharmacokinetics of recombinant proteins. Here, growth media supplemented with metal ions is shown to modulate the protein glycosylation profile of recombinant proteins expressed in a variety of eukaryotic cell lines. In particular, millimolar amounts of ferric salts (e.g. ferric nitrate, ferric citrate,... Abbvie Inc

05/18/17 / #20170135994

Nampt inhibitors

... Abbvie Inc

05/18/17 / #20170137496

Methods to control protein heterogeneity

The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells.... Abbvie Inc

05/18/17 / #20170137860

Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides

The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.... Abbvie Inc

05/11/17 / #20170129902

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.... Abbvie Inc

05/11/17 / #20170130191

Cell culture improvements

The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.... Abbvie Inc

05/04/17 / #20170121403

Modulated lysine variant species compositions and methods for producing and using the same

The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in... Abbvie Inc

04/27/17 / #20170114077

Heterocyclic kinase inhibitors

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.... Abbvie Inc

04/20/17 / #20170107038

Medication packaging and dispensing system

A medication packaging and dispensing system is provided. The system may include a plurality of medication booklets containing medication and a tray that is configured to retain the medication booklets. Each medication booklet may include a sequential tab assembly of pull tabs that aligns with a plurality of front cutouts... Abbvie Inc

04/06/17 / #20170096424

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Abbvie Inc

04/06/17 / #20170096470

Dual specific binding proteins having a receptor sequence

Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.... Abbvie Inc

03/30/17 / #20170088611

Single-chain multivalent binding protein compositions and methods

Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).... Abbvie Inc

03/16/17 / #20170072065

Anti-egfr antibodies and antibody drug conjugates

The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.... Abbvie Inc

03/16/17 / #20170073329

Salt and crystalline forms thereof of a drug

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.... Abbvie Inc

03/16/17 / #20170073353

Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use

and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions... Abbvie Inc

03/16/17 / #20170073420

Methods for treating relapsing forms of multiple sclerosis

Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat multiple sclerosis, including relapsing forms of multiple sclerosis such as relapsing-remitting multiple sclerosis or relapsing-secondary progressive multiple sclerosis.... Abbvie Inc

03/09/17 / #20170065575

Nampt inhibitors

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.... Abbvie Inc

03/09/17 / #20170066765

Crystalline bromodomain inhibitors

N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.... Abbvie Inc

03/02/17 / #20170056403

Methods of administering elagolix

The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the... Abbvie Inc

03/02/17 / #20170057966

Fused heterocyclic compounds as s1p modulators

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.... Abbvie Inc

03/02/17 / #20170057981

Anti-viral compounds

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Abbvie Inc

03/02/17 / #20170058027

Il-1 binding proteins

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.... Abbvie Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Abbvie Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Abbvie Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###